The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study

Journal of the American College of Cardiology

Volumn 40, Issue 7, 2002, Pages 1199-1204

  Faxon, David P ^a,f   Gibbons, Raymond J ^b   Chronos, Nicolas A F ^c   Gurbel, Paul A ^d   Sheehan, Florence ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

^d SINAI HOSPITAL OF BALTIMORE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD18 ANTIGEN; INTEGRIN RECEPTOR; ROVELIZUMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOPLASTY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION; THORAX PAIN; URINARY TRACT INFECTION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; ANTIGENS, CD18; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INTEGRINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TECHNETIUM TC 99M SESTAMIBI; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0037010009     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02136-8     Document Type: Article

References (36)

1. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2000;1-39.
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994;343:311-22.
3. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword. J Clin Invest 1985;76:1713-19.
4. Hearse D, Bolli R. Reperfusion induced injury: manifestations, mechanisms and clinical relevance. Cardiovasc Res 1992;26:101-8.
5. Maxwell SRJ, Lip GYH. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 1997;58:95-117.
6. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995;91:1872-85.
7. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55.
8. Grisham MB, Granger DN, Lefer DJ. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Free Radical Biol Med 1998;25:404-33.
9. Lefer DJ, Shadelya SML, Serrano CV, Becker LC, Kuppusamy P, Zweier JL. Cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation 1993;88:1779-87.
10. Tanaka M, Brook SE, Richard VJ, et al. Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 1993;87:526-35.
11. Aversano T, Zhou W, Nedelman M, Nadada M, Weisman H. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. J AM Coll Cardiol 1995;25:781-8.
12. Arai M, Lefer DJ, So T, DePaula A, Aversano T, Becker LC. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 1996;27:1278-85.
13. Horwitz LD, Kaufman D, Kong Y. An antibody to leukocyte integrins attenuates coronary vascular injury due to ischemia and reperfusion in dogs. Am J Physiol 1997;272:H618-24.
14. Palazzo AJ, Jones SP, Giron WG, Anderson DC, Granger DN, Lefer DJ. Myocardial ischemia-reperfusion injury in CD18 and ICAM-1 deficient mice. Am J Physiol 1998;275:H2300-7.
15. Yenari MA, Kunis D, Sun GH, et al. Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol 1998;153:223-33.
16. Gibson CM, Cannon CP, Daley WL, et al., for the TIMI 4 Study Group. TIMI frame count. A quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
17. O'Connor MK, Gibbons RJ, Juni JE. Quantitative myocardial SPECT for infarct sizing: feasibility of a multicenter trial evaluated using a cardiac phantom. J Nucl Med 1995;36:1130-6.
18. Gibbons RJ, Christian TF, Hopfenspirger M, et al. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention. J Am Coll Cardiol 1994;24:616-23.
19. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m) Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000;101:101-8.
20. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55.
21. Sheridan FM, Cole PG, Ramage D. Leukocyte adhesion to the coronary microvaculature during ischemia and reperfusion in an in vivo canine model. Circulation 1996;93:1734-87.
22. low polymorphonudear leukocytes in the circulating pool of peripheral blood during myocardial infaction correlates with neutrophilia and with the size of the infarct. Clin Cardiol 1999;22:721-6.
23. Kassirer M, Zeltser D, Prochorov V, et al. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. Am Heart J 1999;138:555-9.
24. Engler RL, Schmid-Schonbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983;111:98-111.
25. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction. Importance of microvascular reperfusion injury on clinical outcome. Circulation 1999;99:1972-7.
26. Gibson CM, Murphy SA, Rizzo MJ, et al., for the Thrombolysis in Myocardial Infarction (TIMI) Study Group. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999;99:1945-50.
27. Gibson CM, Cannon CP, Murphy SA, et al., for the TIMI (Thrombolysis In Myocardial Infarction) Study Group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-30.
28. Wall TC, Califf RM, Blandenship J, et al. Intravenous fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. Circulation 1994;90:114-20.
29. Rusnak JM, Kopecky SL, Clements IP, et al., for the FESTIVAL Investigators. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (The FESTIVAL Study). Am J Cardiol 2001;88:482-7.
30. Bronfman S. Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 1999;138:S1-5.
31. Baran K, Nguyen M, McKendall GR, et al., for the LIMIT AMI Investigators. Double-blind, randomized trial of an anti-CD18 anti-body in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Limitation of Myocardial Injury following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study. Circulation 2001;104:2778-85.
32. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
33. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 1997;96:192-201.
34. EMIP-FR Pilot Study Group. Free radicals, reperfusion and myocardial infarction therapy: European Myocardial Infarction Project - Free Radicals Pilot Study. Eur Heart J 1993;14 Suppl G:48-51.
35. Mahaffey KW, Puma JA, Barbagelata A, et al, for the AMISTAD Investigators. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 1999;34:1711-20.
36. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992;85:893-904.